trending Market Intelligence /marketintelligence/en/news-insights/trending/PZKJH8AT9Utg6kQuaVOjAw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

US FDA approves Teva's newer asthma inhaler

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

US FDA approves Teva's newer asthma inhaler

The U.S. Food and Drug Administration approved Teva Pharmaceutical Industries Ltd.'s QVAR RediHaler, an inhaler for the maintenance treatment of asthma in patients aged 4 years and older.

The treatment eliminates the need for hand-breath coordination during inhalation, Teva said in a news release.

The approval was supported by data from a phase 1 study and four phase 3 studies.

The QVAR metered-dose inhaler with dose counter, the currently available form of the treatment, was approved by the U.S. FDA in 2014.

Teva plans to discontinue selling the current formulation of QVAR when the QVAR RediHaler is launched in the first quarter of 2018 in 40- and 80-micrograms strengths.